Skip to content
OpenCapital
Get started

Kalaris Therapeutics Inc KLRS Q3 2025 earnings

Reported November 12, 2025 · Before market open

EPS-$0.64Beat by $0.02
EPS estimate-$0.66

Next report

Aug 12, 2026 (In 2 weeks)
EPS estimate-$0.50

Financials

Q3 2025

Income statement

See full
Operating income-$12.7M+66.3%
Net income-$11.9M+68.8%
EPS (diluted)-$0.64+97.7%

Balance sheet

See full
Cash & equivalents$42.4M+2,116%
Total debt$1.5M—
Total equity$41.9M+147%
Total assets$81.2M-33.8%

Cash flow

See full
Operating cash flow-$11.3M-162%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$108.1M—
Enterprise value$67.26M—

Returns & leverage

See full
Debt / equity0×—
Current ratio12.9×-73.9×

Versus estimates

Diluted EPS

Q1 2026-$0.46Beat by $0.06Q4 2025-$0.44Beat by $0.12
Q3 2025-$0.64Beat by $0.02
Q2 2025-$0.61Miss by $0.10Q1 2025-$2.52Miss by $1.74Q4 2024-$3.64Miss by $0.88

Ask the moment Kalaris Therapeutics Inc reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Kalaris Therapeutics Inc report Q3 2025 earnings?
Kalaris Therapeutics Inc (KLRS) reported Q3 2025 earnings on November 12, 2025 before market open.
What were Kalaris Therapeutics Inc's Q3 2025 revenue and EPS?
Kalaris Therapeutics Inc reported eps of $-0.64 for Q3 2025.
Did Kalaris Therapeutics Inc beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.66 by $0.02.
How did Kalaris Therapeutics Inc's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 1500.0% from $-0.04.
Where can I find Kalaris Therapeutics Inc's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-276060) and the 10-Q periodic report (0001193125-25-277464) directly on SEC EDGAR. The filing index links above go to sec.gov.